Discussion In the present study, we provided direct evidence that GSDMD-FL and GSDMD-N were both upregulated in hindlimb ischemic injury
In NSCLC, MEG3 suppresses tumor proliferation and metastasis via the miR-21-5p/PTEN and MDM2/p53 axes, while in pulmonary hypertension, it promotes vascular remodeling by sponging miR-328-3p and upregulating IGF1R, highlighting its dual context-dependent roles in tumor suppression and vascular dysfunction [109,110,111]
Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157
Rosenthal, S